---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-073817"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2023-06-22T23:59:59+00:00"
generated_at: "2026-06-13T19:03:32.363985+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# uniQure reports $100M HEMGENIX milestone; AMT-130 shows preserved function at 24 months in HD trial

## Summary
- $100M milestone achieved from CSL Behring for first US commercial sale of HEMGENIX (hemophilia B gene therapy); payment due within 30 days.
- AMT-130 well-tolerated; no treatment-emergent adverse events led to discontinuation. DSMB recommends continuing development.
- Low-dose cohort showed preserved function at 24 months; TMS improved 1.8 points vs natural history, TFC 0.8, cUHDRS 0.9.
- Mean CSF NfL 12.9% below baseline at 24 months in low-dose cohort vs predicted 22.9% increase in natural history.
- Plan to complete EU enrollment in Q3 2023, start third US cohort in H2 2023, and hold regulatory interactions by Q1 2024.

## SEC filing metadata
- accession: 0001104659-23-073817
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2023-06-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465923073817/0001104659-23-073817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465923073817/tm2319377d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-073817
- JSON: https://secwatch.observer/filing/0001104659-23-073817.json
- Plain text: https://secwatch.observer/filing/0001104659-23-073817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.